P1 receptors and cytokine secretion

Purinergic Signalling

Volumn 3, Issue 1-2, 2007, Pages 13-25

  Abbracchio, Maria P ^a   Ceruti, Stefania ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adenosine; Asthma; Central nervous system; Chronic heart failure; Cytokines; Immune cells; Inflammation

Indexed keywords

EID: 33947660450     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-006-9033-z     Document Type: Review

References (84)

1. Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264
2. Linden J (2005) Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67:1406-1413
3. Hirschhorn R, Grossman J, Weissmann G (1970) Effect of cyclic 3′-5′ adenosine monophosphate and theophylline on lymphocyte transformation. Proc Soc Exp Biol Med 133:1361-1365
4. Henney CS, Lichtenstein LM (1971) The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol 107:610-612
5. Cronstein BN, Kramer SB, Rosenstein ED et al (1985) Adenosine modulates the generation of superoxide anion by stimulated human neutrophils via interaction with a specific cell surface receptor. Ann NY Acad Sci 451:291-301
6. Firestein GS (1996) Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res 39:371-376
7. 2A purinergic receptor-mediated signalling in murine T cells. J Biol Chem 272:25881-25889
8. Yaar R, Jones MR, Chen JF, Ravid K (2005) Animal models for the study of adenosine receptor function. J Cell Physiol 202:9-20
9. Sitkovsky MV, Lukashev D, Apasov S et al (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22:657-682
10. Sitkovsky MV, Ohta A (2005) The "danger" sensors that STOP the immune response: The A2 adenosine receptors? Trends Immunol 26:299-304
11. Matzinger P (2002) The danger model: A renewed sense of self. Science 296:301-305
12. Marchetti B, Abbracchio MP (2005) To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci 26:517-525
13. Braun N, Lenz C, Gillardon F et al (1997) Focal cerebral ischemia enhances glial expression of ecto-5′-nucleotidase. Brain Res 766:213-226
14. Raskovalova T, Huang X, Sitkovsky MV et al (2005) Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 175:4383-4391
15. Panther E, Corinti S, Idzko M et al (2003) Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 101:3985-3990
16. Sitkovsky MV (2003) Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 65:493-501
17. Lukashev D, Ohta A, Apasov S et al (2004) Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 173:21-24
18. Mohsenin A, Blackburn MR (2006) Adenosine signaling in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 12:54-59
19. Heijink IH, Van Oosterhout AJM (2005) Targeting T cells for asthma. Curr Opin Pharmacol 5:227-231
20. Peachell P (2005) Targeting the mast cell in asthma. Curr Opin Pharmacol 5:251-256
21. Brightling CE, Bradding P, Symon FA et al (2002) Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346:1699-1705
22. Cushley MJ, Tattersfield AE, Holgate ST (1983) Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects. Br J Clin Pharmacol 15:161-165
23. Oosterhoff Y, de Jong JW, Jansen MA et al (1993) Airway responsiveness to adenosine 5′-monophosphate in chronic obstructive pulmonary disease is determined by smoking. Am Rev Respir Dis 147:553-558
24. Holgate ST (2005) The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol 145:1009-1015
25. Phillips GD, Ng WH, Church MK, Holgate ST (1990) The response of plasma histamine to bronchoprovocation with methacholine, adenosine 5′-monophosphate, and allergen in atopic nonasthmatic subjects. Am Rev Respir Dis 141:9-13
26. van de Berge M, Polosa R, Kerstjens HA, Postma DS (2004) The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 114:737-746
27. Spicuzza L, Bonfiglio C, Polosa R (2003) Research applications and implications of adenosine in diseased airways. Trends Pharmacol Sci 24:409-413
28. van den Berge M, Kerstjens HA, de Reus DM et al (2004) Provocation with adenosine 5′-monophosphate, but not methacholine, induces sputum eosinophilia. Clin Exp Allergy 34:71-76
29. Fan M, Mustafa J (2006) Role of adenosine in airway inflammation in an allergic mouse model of asthma. Int Immunopharmacol 6:36-45
30. Meade CJ, Worall L, Hayes D, Protin U (2002) Induction of interleukin 8 release from the HMC-1 mast cell line: Synergy between stem cell factor and activators of the adenosine A2b receptor. Biochem Pharmacol 64:1163-1173
31. 2B -mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 172:7726-7733
32. Fozard JR (2003) The case for a role for adenosine in asthma: Almost convincing? Curr Opin Pharmacol 3:264-269
33. Dent G, Rabe KF (2000) Theophylline. Lung Biol Health Dis 145:77-124
34. 2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am J Respir Cell Mol Biol 32:2-8
35. 2B adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am J Respir Cell Mol Biol 30:118-125
36. McNamara N, Gallup M, Khong A et al (2004) Adenosine up-regulation of the mucin gene, MUC2, in asthma. FASEB J 18:1770-1772
37. Feoktistov I, Garland EM, Goldstein AE et al (2001) Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol 62:1163-1173
38. 2B receptors from rat, guinea pig and dog. Eur J Pharmacol 475:79-84
39. Blackburn MR, Datta SK, Kellems RE (1998) Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273:5093-5100
40. Chunn JL, Young HW, Banerjee SK et al (2001) Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J Immunol 167:4676-4685
41. Sun C-X, Young HW, Molina JG et al (2005) A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 115:35-43
42. Rorke S, Holgate ST (2002) Targeting adenosine receptors: Novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Am J Respir Med 1:99-105
43. Newby AC (1984) Adenosine and the concept of "retaliatory metabolites". Trends Biochem Sci 9:42-44
44. Newby AC, Worku Y, Holmquist CA (1985) Adenosine formation. Evidence for a direct biochemical link with energy metabolism. Adv Myocardiol 6:273-284
45. Melani A, Turchi D, Vannucchi MG, Cipriani S, Gianfriddo M, Pedata F (2005) ATP extracellular concentrations are increased in the rat striatum during in vivo ischemia. Neurochem Int 47:442-448
46. Haskó G, Pacher P, Vizi ES, Illes P (2005) Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 26:511-516
47. Dunwiddie TV, Masino SA (2001) The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31-55
48. Stone TW (2002) Purines and neuroprotection. Adv Exp Med Biol 513:249-280
49. Panickar KS, Norenberg MD (2005) Astrocytes in cerebral ischemic injury: morphological and general considerations. Glia 50:287-298
50. Gebicke-Haerter PJ, Christoffel F, Timmer J et al (1996) Both adenosine A1- and A2-receptors are required to stimulate microglial proliferation. Neurochem Int 29:37-42
51. Si QS, Nakamura Y, Schubert P et al (1996) Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. Exp Neurol 137:345-349
52. Ciccarelli R, Di Iorio P, Bruno V et al (1999) Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100b protein from cultured astrocytes. Glia 27:275-281
53. Schwaninger M, Neher M, Viegas E et al (1997) Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. J Neurochem 69:1145-1150
54. Wittendorp MC, Boddeke HWGM, Biber K (2004) Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes. Glia 46:410-418
55. Brodie C, Blumberg CM, Jacobson KA (1998) Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett 429:139-142
56. Fiebich BL, Biber K, Lieb K et al (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18:152-160
57. 2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 95:919-929
58. Heese K, Fiebich BL, Bauer J, Otten U (1997) Nerve growth factor (NGF) expression in rat microglia is induced by adenosine A2a-receptors. Neurosci Lett 231:83-86
59. Angulo E, Casado V, Mallol J et al (2003) A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol 13:440-451
60. Hammarberg C, Schulte G, Fredholm BB (2003) Evidence for functional adenosine A3 receptors in microglia cells. J Neurochem 86:1051-1054
61. Lee JY, Jhun BS, Oh YT et al (2006) Activation of adenosine A 3 receptor suppresses lipopolysaccharide-induced TNF-α production through inhibition of PI 3-kinase/Akt and NF-κB activation in murine BV2 microglial cells. Neurosci Lett 396:1-6
62. Tsutsui S, Schnermann J, Noorbakhsh F et al (2004) A 1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 24:1521-1529
63. Fotheringham J, Mayne M, Holden C et al (2004) Adenosine receptors control HIV-1 Tat-induced inflammatory responses through protein phosphatase. Virology 327:186-195
64. Picano E, Abbracchio MP (2000) Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. Brain Res Bull 52:75-82
65. Pera J, Zawadzka M, Kaminska B, Szczudlik A (2004) Influence of chemical and ischemic preconditioning on cytokine expression after focal brain ischemia. J Neurosci Res 78:132-140
66. Biber K, Lubrich B, Fiebich BL et al (2001) Interleukin-6 enhances expression of adenosine A(1) receptor mRNA and signaling in cultured rat cortical astrocytes and brain slices. Neuropsychopharmacology 24:86-96
67. Brambilla R, Cottini L, Fumagalli M et al (2003) Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 43:190-194
68. Trincavelli ML, Marroni M, Tuscano D et al (2004) Regulation of A2B adenosine receptor functioning by tumour necrosis factor α in human astroglial cells. J Neurochem 91:1180-1190
69. Rees DA, Scanlon MF, Ham J (2003) Adenosine signalling pathways in the pituitary gland: One ligand, multiple receptors. J Endocrinol 177:357-364
70. Levine B, Kalman J, Mayer L et al (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 223:236-241
71. Mann DL (2002) Inflammatory mediators and the failing heart. Past, present, and the foreseeable future. Circ Res 91:988-998
72. Bozkurt B, Kribbs S, Clubb FJ Jr et al (1998) Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97:1382-1391
73. Thaik CM, Calderone A, Takahashi N, Colucci WS (1995) Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 96:1093-1099
74. Kubota T, McTiernan CF, Frye C et al (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81:627-635
75. Torre-Amione, G, Kapadia S, Lee J et al (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93:704-711
76. Mann DL (1996) The effect of tumor necrosis factor-alpha on cardiac structure and function: A tale of two cytokines. J Card Fail 2(4 Suppl):S165-S172
77. Schreiner GF (1998) Immune modulation of cardiac cell function. Trans Am Clin Climatol Assoc 109:39-49
78. Seta Y, Shan K, Bozkurt B et al (1996) Basic mechanisms in heart failure: The cytokine hypothesis. J Card Fail 2:243-249
79. Villareal F, Zimmermann S, Makhsudova L et al (2003) Modulation of cardiac remodeling by adenosine: In vitro and in vivo effects. Mol Cell Biochem 251:17-26
80. Varani K, Laghi-Pasini F, Camurri A et al (2003) Changes of peripheral adenosine receptors in chronic heart failure and cardiac transplantation. FASEB J 17:280-282
81. Wagner DR, McTieman C, Sanders VJ, Feldman AM (1998) Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation 97:521-524
82. 2A adenosine receptor expression by TNFalpha in PBMC of patients with CHF: A regulatory mechanism of inflammation. J Card Fail 11:67-73
83. Xaus J, Mirabet M, Lloberas J et al (1999) IFN-gamma up-regulates the A2A adenosine receptor expression in macrophages: A mechanism of macrophage deactivation. J Immunol 162:3607-3614
84. Khoa ND, Montesinos MC, Reiss AB et al (2001) Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol 167:4026-4032